Ronald C. DeConti, MD

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  Yale University School of Medicine - Medical Oncology; Pharmacology

RESIDENCY:
          •  North Carolina Memorial Hospital - Medicine

MEDICAL SCHOOL:
          •  Yale University School of Medicine - MD

• May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Mar. Pubmedid: 23468387.


• Allam-Nandyala P, Bui MM, Deconti R, Purohit C, Altiok S. Squamous cell carcinoma with rhabdoid phenotype of skin/soft tissue in a transplant patient: An exceptional case and review of the literature. Diagn Cytopathol. 2013 Feb;41(2):159-163. Pubmedid: 23335454.


• Deconti RC. Chemotherapy of squamous cell carcinoma of the skin. Semin Oncol. 2012 Apr;39(2):145-149. Pubmedid: 22484186.


• Donepudi S, Deconti RC, Samlowski WE. Recent advances in the understanding of the genetics, etiology, and treatment of merkel cell carcinoma. Semin Oncol. 2012 Apr;39(2):163-172. Pubmedid: 22484188.


• Glass LF, Deconti RC, Sondak VK. Introduction: advanced cutaneous malignancies. Semin Oncol. 2012 Apr;39(2):132-133. Pubmedid: 22484183.


• Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012 Feb;106(1):85-91. Pubmedid: 22127285. Pmcid: PMC3251861.


• Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011 Aug;117(15):3374-3382. Pubmedid: 21246525. Pmcid: PMC3135694.


• Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon ?-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011 Apr;67(3):657-666. Pubmedid: 20509027. Pmcid: PMC3043235.


• Bedikian AY, Deconti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011 Apr;22(4):787-793. Pubmedid: 20855467.


• DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer. 2011 Mar;103(10):1548-1553. Pubmedid: 20924376. Pmcid: PMC2990578.


• Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Witter MT, Flaherty LE, Sondak VK. A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am J Clin Oncol. 2010 Oct;33(5):495-499. Pubmedid: 20019577. Pmcid: PMC2978644.


• Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010 Oct;33(8):817-827. Pubmedid: 20842055.


• Kudchadkar R, Deconti R. Systemic treatments for merkel cell carcinoma. Curr Probl Cancer. 2010 Jan;34(1):97-107. Pubmedid: 20371077.


• Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-692. Pubmedid: 19620591.


• Daud AI, Dawson J, Deconti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr;15(7):2479-2487. Pubmedid: 19318485.


• Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol. 2009 Apr;27(12):1983-1991. Pubmedid: 19289616.


• Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec;26(36):5896-5903. Pubmedid: 19029422. Pmcid: PMC2645111.


• Homsi J, Simon G, Garrett C, Springett G, DeConti R, Chiappori A, Munster PN, Burton M, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan D, Daud A. Phase I Trial of Poly-L-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2007 Oct;13(19):5855-5861. Pubmedid: 17908979.


• Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WR, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007 May;25(15):2078-2085. Pubmedid: 17513813.


• M?nster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May;25(15):1979-1985. Pubmedid: 17513804.


• Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct;24(29):4738-4745. Pubmedid: 16966688.


• Gibson MK, Li Y, Murphy B, Hussain M, DeConti RC, Ensley J, Forastiere AA. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxedl in advanced head and neck cancer (E1395): an Intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 May;23(15):3562-3567. Pubmedid: 15908667.


• Langer C, Li Y, Jennings T, DeConti R, Nair S, Cohen R, Forastiere A. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of theEastern Cooperative Oncology Group. Cancer Invest. 2004;22(6):823-831. Pubmedid: 15641479.


• Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol. 2001;19(4):1088-1095. Pubmedid: 11181673.


• Smith D, Messina J, Perrott R, Berman C, Reintgen D, Cruse C, Glass F, DeConti R, Trotti A, Fenske N. Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Cancer Control. 2000;7(1):72-83. Pubmedid: 10740663.


• Flood W, Lee D, Trotti A, Spencer S, Murphy B, Khuri F, DeConti R, Wheeler R, Forastiere A. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin Rad Oncol. 1999;9(2):61-69. Pubmedid: 10210542.


• Joseph E, Glass F, Glass J, Messina J, DeConti R, Cruse C, Rapaport D, Berman C, Fenske N, Reintgen D. The results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol. 1998;5:119-125. Pubmedid: 9527264.


• Forastiere A, Shank D, Neuberg D, Taylor S, DeConti R, Adams G. Final report of phase II evaluation of paclitaxel in advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial [PA390]. Cancer. 1998;82(11):2270-2274. Pubmedid: 9610709.


• Shivers S, Wang X, Li W, Joseph E, Messina J, Glass L, DeConti R, Cruse W, Berman C, Fenske N, Lyman G, Reintgen D. Molecular staging of malignant melanoma - correlation with clinical outcome. Jama. 1998;280(16):1410-1415. Pubmedid: 9801000.


• Brobeil A, Berman C, Cruse C, DeConti R, Cantor A, Lyman G, Rapaport D, Joseph E, Wells K, Reintgen D. Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. Ann Surg Oncol. 1998;5(4):376-383. Pubmedid: 9641461.


• Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, Glass LF. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer. 1998;83(1):148-157. Pubmedid: 9655305.


• Mir L, Glass L, Sersa G, Teissie J, Domenge C, Miklavcic D, Jaroszeski M, Orlowski S, Reintgen D, Rudolf Z, Belehradek M, Gilbert R, Rols M, Belehradek J, Bachaud J, DeConti R, Stabuc B, Cemazar M, Coninx P, Heller R. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Br J Cancer. 1998;77(12):2336-2342. Pubmedid: 9649155.


• Kamath D, Rapaport D, DeConti R, Cruse C, Wells K, Glass L, Messina J, Fenske N, Brobeil A, Berman C, Puleo C, Reintgen D. Redefining cutaneous lymphatic flow: the necessity of preoperative lymphoscintigraphy in the management of malignant melanoma. J Fla Med Assoc. 1997;84(3):182-187. Pubmedid: 9143170.


• Cruse C, Reintgen D, Glass F, Messina J, Trotti, III A, DeConti R. Clinical practice guidelines: neuroendocrine tumors of the skin. Cancer Control. 1997;4:258-260. Pubmedid: noPMID.


• Brobeil A, Rapaport D, Wells K, Cruse C, Glass F, Fenske N, Albertini J, Miliotis G, Messina J, DeConti R, Berman C, Shons A, Cantor A, Reintgen D. Multiple primary melanomas: implications for screening and follow-up programs. Ann Surg Oncol. 1997;4:19-23. Pubmedid: 8985513.


• Kamath D, Cantor A, Glass L, Fenske N, Cruse C, Wells K, Rapaport D, DeConti R, Messina J, Reintgen D. Florida's undeclared epidemic: malignant melanoma. J Fla Med Assoc. 1997;84(3):161-165. Pubmedid: 9143167.


• Heller R, Jaroszeski M, Glass L, Messina J, Rapaport D, DeConti R, Fenske N, Gilbert R, Mir L, Reintgen D. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 1996 Mar;77(5):964-971. Pubmedid: 8608491 .


• Remick S, Chmura M, Bromberg C, Spron J, Healey B, Hilstro J, DeConti R, Horton J, Ruckdeschel J, Harper G. Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Am J Clin Oncol. 1996;19(3):125-131. Pubmedid: 8610634.


• Heller R, Jaroszeski M, Glass L, Messina J, Rapaport D, DeConti R, Fenske N, Gilbert R, Mir L, Reintgen D. Phase I/II trial of cutaneous and subcutaneous malignancies using electrochemotherapy. Cancer. 1996;75(5):964-971. Pubmedid: 8608491.


• Albertini J, Cruse C, Rapaport D, Wells K, DeConti R, Berman C, Jared K, Messina J, Lyman G, Glass L, Fenske N, Reintgen D. Intraoperative radiolymphoscinitigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996;223(2):217-224. Pubmedid: 8597518.


• Meliotis G, Albertini J, Berman C, Heller R, Messina J, Glass L, Cruse C, Rapaport D, Puleo C, Fenske N, Petsofglov C, DeConti R, Lyman G. The tumor biology of melanoma nodal metastasis. Am Surg. 1996;62:81-88. Pubmedid: 8540654.


• Reintgen D, Albertini J, Miliotes G, Berman C, Cruse C, Fenske N, Glasser S, Puleo C, Wang X, Wells K, Rapaport D, DeConti R, Messina J, Heller R. The accurate staging and modern day treatment of malignant melanoma. Cancer Res Ther Cont. 1995;4:183-197. Pubmedid: noPMID.


• Reintgen D, Albertini J, Berman C, Cruse C, Fenske N, Glass L, Puleo C, Wang X, Wells K, Rapaport D, DeConti R, Messina J, Heller R. Accurate nodal staging of malignant melanoma. Cancer Control. 1995;2(5):405-414. Pubmedid: 10862181.


• Wang X, Heller R, Cruse C, VanVoorhis N, Glass L, Fenske N, Berman C, Leo-Messina J, Rapaport D, Wells K, DeConti R, Moscinski L, Stankard C, Puleo C, Reintgen D. Detection of submicroscopic lymph node metasases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994;220:768-774.


• DeConti R. Perspectives on chemotherapy of head and neck cancer. Cancer Control. 1994;1(1):24-34.


• Forastiere A, Neuberg D, Taylor S, DeConti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group Trial. Monogr Natl Cancer Inst. 1993;14:181-184.


• DeConti R. Chemotherapy of head and neck cancer. In: Hand book of cancer chemotherapy. Little, Brown And Co.; 1995.


• DeConti R. Chemotherapy of head and neck cancer. In: Handbook of Cancer Chemotherapy. 5th ed. Philadelphia. Lippincott Williams And Wilkins; 1999.


• Marsh JC, DeConti RC, Hubbard SP. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962). Cancer Chemother Rep. 1971 Dec;55(5):599-606. Pubmedid: 4334161.

Dr. Ronald DeConti is Hospital Medical Director, at Moffitt Cancer Center, as well as a senior member of the Departments of Cutaneous Oncology and Head & Neck Oncology.  He is also a professor at the University of South Florida College of Medicine’s Department of Oncologic Sciences and Department of Internal Medicine.

Dr. DeConti's research interest focuses on clinical trials for the treatment of melanoma and head and neck cancers.

A graduate of Yale University School of Medicine, Dr. DeConti completed his residency in internal medicine at the University of North Carolina and a research fellowship in medicine and pharmacology at Yale. 

Prior to joining Moffitt in 1993, Dr. DeConti held various hospital and academic leadership positions, including chief of Oncology and medical director of the Comprehensive Cancer Center at Albany Veterans Administration Medical Center and professor of medicine at Albany Medical College in NY. 

Before that, he served as associate clinical professor of medicine at Tufts University School of Medicine in Boston, adjunct associate professor at the University of Massachusetts School of Public Health and associate clinical professor of medicine at Yale.

Dr. DeConti is a book and manuscript reviewer for several medical journals, including JAMA and the Journal of Clinical Oncology.  He has been widely published in numerous professional publications.